Astorg and Montagu, two leading pan-European private equity investors, today announced that they have entered into a binding agreement with Caisse de dépôt et placement du Québec (CDPQ), a leading Canadian institutional asset manager, for the sale of a significant minority stake in Sebia.
Headquartered in Lisses (Paris, France), Sebia is a global multi-specialty in-vitro diagnostics company focusing on oncology, genetic haemoglobin and metabolic disorders. The company is one of the pioneers of clinical electrophoresis.
With the support of CDPQ, Sebia intends to pursue the successful strategy of the past years, based on the reinforcement of its undisputed leadership position in multiple myeloma diagnostics, the global expansion of its diabetes franchise, and the continued search for other highly-promising applications for its differentiated technology.
Benoît Adelus, CEO of Sebia said: “We welcome CDPQ’s entry in Sebia’s capital. Over the last years, Sebia has kept upgrading its technology and successfully applying it to attractive niche markets where it provides clear medical benefits. Having CDPQ as a long-term partner to the company will contribute to our development in line with this strategy.”
“The accuracy, efficiency and speed of Sebia’s tests, coupled with its proven technology, make them critical to the global medical community,” said Stéphane Etroy, Executive Vice-President and Head of Private Equity at CDPQ. “The company’s rapid growth and development into adjacent therapeutics areas is evidence not only of the strength of its management team, but also of its resilient business model. We will work with our partners to support the company as it expands into new opportunities in the diagnostics sector.”
The proposed transaction is subject to customary clearance of regulatory authorities.